Loading oncology approvals…
Loading oncology approvals…
Regulatory
Every record is one authority's decision for one application or DIN, shown with its jurisdiction, date, indication text as published and status. A molecule approved in one jurisdiction for one indication is not 'approved' in general.
RegulatoryDevelopment pipeline →Methodology
Coverage
Counts of records, not of drugs approved: one application can carry several dated records (original approval, efficacy supplements, one row per DIN in Canada).
Approval records
4,342
Distinct drugs
373
Records naming a cancer
982
Dated in the last 12 months
179
| Authority | Jurisdiction | Records | Drugs | In force | Withdrawn / cancelled | Last 12 months | Latest dated record |
|---|---|---|---|---|---|---|---|
| FDA | US | 2,343 | 304 | 2,343 | 0 | 115 | Sep 18, 2026 |
| Health Canada | CA | 1,538 | 273 | 979 | 559 | 44 | Sep 22, 2026 |
| EMA | EU | 461 | 246 | 386 | 75 | 20 | Sep 18, 2026 |
Data updated 23 hours agoSource updated unknown3 authority · jurisdiction pairs ingested
Feed
Latest approval date first; records without a date are listed last. Filters combine.
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Nov 13, 2023 | Ibrutinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as IMBRUVICA (DIN 02540215) under ATC L01EL01 IBRUTINIB. Indications are not published in the Drug Product Database —… | DIN02540215 | approvedsource: Marketed | health-canada-dpd |
| Nov 1, 2023 | Apalutamide | Health Canada CA | cancer not stated in this record | Marketed in Canada as ERLEADA (DIN 02540185) under ATC L02BB05 APALUTAMIDE. Indications are not published in the Drug Product Database —… | DIN02540185 | approvedsource: Marketed | health-canada-dpd |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Oct 27, 2023 | Paclitaxel | Health Canada CA | cancer not stated in this record | Marketed in Canada as PACLITAXEL POWDER FOR INJECTABLE SUSPENSION NANOPARTICLE, ALBUMIN-BOUND PACLITAXEL (DIN 02496097) under ATC L01CD01… |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Sep 18, 2023 | Sunitinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as AURO-SUNITINIB (DIN 02532190) under ATC L01EX01 SUNITINIB. Indications are not published in the Drug Product Database… | DIN02532190 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Aug 31, 2023 | Plerixafor | Health Canada CA | cancer not stated in this record | Marketed in Canada as PLERIXAFOR INJECTION (DIN 02529815) under ATC L03AX16 PLERIXAFOR. Indications are not published in the Drug Product… | DIN02529815 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Jul 27, 2023 | Anastrozole | Health Canada CA | cancer not stated in this record | Marketed in Canada as AG-ANASTROZOLE (DIN 02534118) under ATC L02BG03 ANASTROZOLE. Indications are not published in the Drug Product… | DIN02534118 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Jun 27, 2023 | Thiotepa | Health Canada CA | cancer not stated in this record | Marketed in Canada as THIOTEPA FOR INJECTION, BP (DIN 02536870) under ATC L01AC01 THIOTEPA. Indications are not published in the Drug… | DIN02536870 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| May 24, 2023 | Sunitinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as SANDOZ SUNITINIB (DIN 02532883) under ATC L01EX01 SUNITINIB. Indications are not published in the Drug Product… | DIN02532883 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Apr 28, 2023 | Abiraterone Acetate | Health Canada CA | cancer not stated in this record | Marketed in Canada as REDDY-ABIRATERONE (DIN 02533251) under ATC L02BX03 ABIRATERONE. Indications are not published in the Drug Product… | DIN |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Mar 28, 2023 | Bortezomib | Health Canada CA | cancer not stated in this record | Marketed in Canada as BORTEZOMIB FOR INJECTION (DIN 02485257) under ATC L01XG01 BORTEZOMIB. Indications are not published in the Drug… | DIN02485257 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Feb 27, 2023 | Mitomycin | Health Canada CA | cancer not stated in this record | Marketed in Canada as MITOMYCIN FOR INJECTION, USP (DIN 02531941) under ATC L01DC03 MITOMYCIN. Indications are not published in the Drug… | DIN |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Jan 30, 2023 | Abiraterone Acetate | Health Canada CA | cancer not stated in this record | Marketed in Canada as JAMP ABIRATERONE (DIN 02529629) under ATC L02BX03 ABIRATERONE. Indications are not published in the Drug Product… | DIN |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Nov 28, 2022 | Pegfilgrastim | Health Canada CA | cancer not stated in this record | Marketed in Canada as LAPELGA (DIN 02529343) under ATC L03AA13 PEGFILGRASTIM. Indications are not published in the Drug Product Database —… | DIN02529343 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Sep 20, 2022 | Sunitinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as TARO-SUNITINIB (DIN 02524082) under ATC L01EX01 SUNITINIB. Indications are not published in the Drug Product Database… | DIN02524082 |
A record is one authority's decision for one application/DIN; the same molecule appears once per jurisdiction and indication. Health Canada DPD does not publish indications — its records state the brand, DIN and ATC class only, and a cancelled or dormant DIN is the status of one product, not of the molecule. FDA cancer mappings come from label text and are flagged probabilistic on the drug page.
| DIN02496097 |
| approvedsource: Marketed |
| health-canada-dpd |
| Oct 23, 2023 | Tremelimumab | Health Canada CA | cancer not stated in this record | Marketed in Canada as IMJUDO (DIN 02541009) under ATC L01FX20 TREMELIMUMAB. Indications are not published in the Drug Product Database —… | DIN02541009 | approvedsource: Marketed | health-canada-dpd |
| Oct 20, 2023 | Teclistamab | Health Canada CA | cancer not stated in this record | Marketed in Canada as TECVAYLI (DIN 02539764) under ATC L01FX24 TECLISTAMAB. Indications are not published in the Drug Product Database —… | DIN02539764 | approvedsource: Marketed | health-canada-dpd |
| Oct 20, 2023 | Teclistamab | Health Canada CA | cancer not stated in this record | Marketed in Canada as TECVAYLI (DIN 02539756) under ATC L01FX24 TECLISTAMAB. Indications are not published in the Drug Product Database —… | DIN02539756 | approvedsource: Marketed | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| Sep 13, 2023 | Niraparib | Health Canada CA | cancer not stated in this record | Marketed in Canada as ZEJULA (DIN 02530031) under ATC L01XK02 NIRAPARIB. Indications are not published in the Drug Product Database — see… | DIN02530031 | approvedsource: Marketed | health-canada-dpd |
| Sep 11, 2023 | Sunitinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as TEVA-SUNITINIB (DIN 02526220) under ATC L01EX01 SUNITINIB. Indications are not published in the Drug Product Database… | DIN02526220 | approvedsource: Marketed | health-canada-dpd |
| Sep 11, 2023 | Sunitinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as TEVA-SUNITINIB (DIN 02526212) under ATC L01EX01 SUNITINIB. Indications are not published in the Drug Product Database… | DIN02526212 | approvedsource: Marketed | health-canada-dpd |
| Sep 11, 2023 | Sunitinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as TEVA-SUNITINIB (DIN 02526204) under ATC L01EX01 SUNITINIB. Indications are not published in the Drug Product Database… | DIN02526204 | approvedsource: Marketed | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| Aug 14, 2023 | Abiraterone Acetate | Health Canada CA | cancer not stated in this record | Marketed in Canada as AKEEGA (DIN 02538563) under ATC L01XK52 NIRAPARIB AND ABIRATERONE. Indications are not published in the Drug Product… | DIN02538563 | approvedsource: Marketed | health-canada-dpd |
| Aug 14, 2023 | Niraparib | Health Canada CA | cancer not stated in this record | Marketed in Canada as AKEEGA (DIN 02538563) under ATC L01XK52 NIRAPARIB AND ABIRATERONE. Indications are not published in the Drug Product… | DIN02538563 | approvedsource: Marketed | health-canada-dpd |
| Aug 14, 2023 | Abiraterone Acetate | Health Canada CA | cancer not stated in this record | Marketed in Canada as AKEEGA (DIN 02538555) under ATC L01XK52 NIRAPARIB AND ABIRATERONE. Indications are not published in the Drug Product… | DIN02538555 | approvedsource: Marketed | health-canada-dpd |
| Aug 14, 2023 | Niraparib | Health Canada CA | cancer not stated in this record | Marketed in Canada as AKEEGA (DIN 02538555) under ATC L01XK52 NIRAPARIB AND ABIRATERONE. Indications are not published in the Drug Product… | DIN02538555 | approvedsource: Marketed | health-canada-dpd |
| Aug 14, 2023 | Bevacizumab | Health Canada CA | cancer not stated in this record | Marketed in Canada as VEGZELMA (DIN 02534177) under ATC L01FG01 BEVACIZUMAB. Indications are not published in the Drug Product Database —… | DIN02534177 | approvedsource: Marketed | health-canada-dpd |
| withdrawnsource: Dormantsince Aug 3, 2026 |
| health-canada-dpd |
| Jul 21, 2023 | Sunitinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as AURO-SUNITINIB (DIN 02532220) under ATC L01EX01 SUNITINIB. Indications are not published in the Drug Product Database… | DIN02532220 | approvedsource: Marketed | health-canada-dpd |
| Jul 21, 2023 | Sunitinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as AURO-SUNITINIB (DIN 02532204) under ATC L01EX01 SUNITINIB. Indications are not published in the Drug Product Database… | DIN02532204 | approvedsource: Marketed | health-canada-dpd |
| Jul 6, 2023 | Anastrozole | Health Canada CA | cancer not stated in this record | Marketed in Canada as ANASTROZOLE (DIN 02529904) under ATC L02BG03 ANASTROZOLE. Indications are not published in the Drug Product Database… | DIN02529904 | approvedsource: Marketed | health-canada-dpd |
| Jul 5, 2023 | Glofitamab | Health Canada CA | cancer not stated in this record | Marketed in Canada as COLUMVI (DIN 02536560) under ATC L01FX28 GLOFITAMAB. Indications are not published in the Drug Product Database — see… | DIN02536560 | approvedsource: Marketed | health-canada-dpd |
| Jul 5, 2023 | Glofitamab | Health Canada CA | cancer not stated in this record | Marketed in Canada as COLUMVI (DIN 02536552) under ATC L01FX28 GLOFITAMAB. Indications are not published in the Drug Product Database — see… | DIN02536552 | approvedsource: Marketed | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| Jun 27, 2023 | Thiotepa | Health Canada CA | cancer not stated in this record | Marketed in Canada as THIOTEPA FOR INJECTION, BP (DIN 02536862) under ATC L01AC01 THIOTEPA. Indications are not published in the Drug… | DIN02536862 | approvedsource: Marketed | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| May 24, 2023 | Sunitinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as SANDOZ SUNITINIB (DIN 02532867) under ATC L01EX01 SUNITINIB. Indications are not published in the Drug Product… | DIN02532867 | approvedsource: Marketed | health-canada-dpd |
| May 24, 2023 | Sunitinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as SANDOZ SUNITINIB (DIN 02532840) under ATC L01EX01 SUNITINIB. Indications are not published in the Drug Product… | DIN02532840 | approvedsource: Marketed | health-canada-dpd |
| May 18, 2023 | Carmustine | Health Canada CA | cancer not stated in this record | Marketed in Canada as CARMUSTINE FOR INJECTION USP (DIN 02531879) under ATC L01AD01 CARMUSTINE. Indications are not published in the Drug… | DIN02531879 | approvedsource: Marketed | health-canada-dpd |
| May 3, 2023 | Crisantaspase | Health Canada CA | cancer not stated in this record | Marketed in Canada as RYLAZE (DIN 02530406) under ATC L01XX02 ASPARAGINASE. Indications are not published in the Drug Product Database —… | DIN02530406 | approvedsource: Marketed | health-canada-dpd |
| May 1, 2023 | Acalabrutinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as CALQUENCE (DIN 02535696) under ATC L01EL02 ACALABRUTINIB. Indications are not published in the Drug Product Database… | DIN02535696 | approvedsource: Marketed | health-canada-dpd |
| May 1, 2023 | Bevacizumab | Health Canada CA | cancer not stated in this record | Marketed in Canada as VEGZELMA (DIN 02534185) under ATC L01FG01 BEVACIZUMAB. Indications are not published in the Drug Product Database —… | DIN02534185 | approvedsource: Marketed | health-canada-dpd |
| May 1, 2023 | Hydroxyurea | Health Canada CA | cancer not stated in this record | Marketed in Canada as RIVA-HYDROXYUREA (DIN 02530260) under ATC L01XX05 HYDROXYCARBAMIDE. Indications are not published in the Drug Product… | DIN02530260 | approvedsource: Marketed | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| Apr 17, 2023 | Azacitidine | Health Canada CA | cancer not stated in this record | Marketed in Canada as AZACITIDINE FOR INJECTION (DIN 02529599) under ATC L01BC07 AZACITIDINE. Indications are not published in the Drug… | DIN02529599 | approvedsource: Marketed | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| Feb 15, 2023 | Thiotepa | Health Canada CA | cancer not stated in this record | Marketed in Canada as THIOTEPA FOR INJECTION USP (DIN 02526425) under ATC L01AC01 THIOTEPA. Indications are not published in the Drug… | DIN02526425 | approvedsource: Marketed | health-canada-dpd |
| Feb 15, 2023 | Thiotepa | Health Canada CA | cancer not stated in this record | Marketed in Canada as THIOTEPA FOR INJECTION USP (DIN 02526417) under ATC L01AC01 THIOTEPA. Indications are not published in the Drug… | DIN02526417 | approvedsource: Marketed | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| Jan 30, 2023 | Bendamustine | Health Canada CA | cancer not stated in this record | Marketed in Canada as BENVYON (DIN 02524309) under ATC L01AA09 BENDAMUSTINE. Indications are not published in the Drug Product Database —… | DIN02524309 | approvedsource: Marketed | health-canada-dpd |
| Jan 17, 2023 | Sunitinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as TARO-SUNITINIB (DIN 02524058) under ATC L01EX01 SUNITINIB. Indications are not published in the Drug Product Database… | DIN02524058 | approvedsource: Marketed | health-canada-dpd |
| Jan 10, 2023 | Enfortumab Vedotin | Health Canada CA | cancer not stated in this record | Marketed in Canada as PADCEV (DIN 02521911) under ATC L01FX13 ENFORTUMAB VEDOTIN. Indications are not published in the Drug Product… | DIN02521911 | approvedsource: Marketed | health-canada-dpd |
| Jan 3, 2023 | Selumetinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as KOSELUGO (DIN 02530147) under ATC L01EE04 SELUMETINIB. Indications are not published in the Drug Product Database —… | DIN02530147 | approvedsource: Marketed | health-canada-dpd |
| Jan 3, 2023 | Selumetinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as KOSELUGO (DIN 02530139) under ATC L01EE04 SELUMETINIB. Indications are not published in the Drug Product Database —… | DIN02530139 | approvedsource: Marketed | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| Nov 7, 2022 | Lutetium (177lu) Vipivotide Tetraxetan | Health Canada CA | cancer not stated in this record | Marketed in Canada as PLUVICTO (DIN 02530198) under ATC V10XX05 LUTETIUM (177LU) VIPIVOTIDE TETRAXETAN. Indications are not published in… | DIN02530198 | approvedsource: Marketed | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| Sep 20, 2022 | Sunitinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as TARO-SUNITINIB (DIN 02524066) under ATC L01EX01 SUNITINIB. Indications are not published in the Drug Product Database… | DIN02524066 | approvedsource: Marketed | health-canada-dpd |
| Sep 16, 2022 | Capmatinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as TABRECTA (DIN 02527405) under ATC L01EP01 CAPMATINIB. Indications are not published in the Drug Product Database —… | DIN02527405 | approvedsource: Marketed | health-canada-dpd |